Background: To assess the mortality, immunological, hematological, and clinical outcomes of children initiating antiretroviral therapy (ART) during the first 5 years (November 2004 -October 2009) of a standardized HIV care and treatment program at the Kalembe-Lembe pediatric hospital in Kinshasa, DRC.
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Apparent virologic failures and blips in a suburban HIV Clinic caused by laboratory errors in a commercial HIV-1 RNA PCR assay P. Cariello * , T. Treadwell MetroWest Medical Center, Framingham, MA, USA Background: The use of commercial assays for quantification of viral RNA is a cornerstone in management of patients with HIV infection. We recently observed an increase in blips and apparent virologic failure not explained by poor adherence or resistance and that resolved when our clinic changed laboratories.
Methods: We retrospectively collected data on patients who were receiving highly active antiretroviral therapy (HAART) from October 2004 until June 2006 and who had one or more HIV-1 plasma viral load (VL) > 1,000 copies/mL. We excluded patients who had interruptions in therapy or had known poor adherence to clinic visits or medications.
Results: Our clinic changed our reference laboratory in December 2005. In the previous 15 months, 38 patients on HAART had at least one VL > 1,000 copies/mL. Six patients had at least one VL > 10,000 copies/mL and 24 patients had more than 2 determinations > 1,000 copies/mL. In the 6 months following the lab change, 37/38 patients had VL < 400, 21/38 < 50, and only one patient had a VL > 600 copies/mL. One year later, 36/38 had no detectable plasma viral RNA. All patients had stable CD4 lymphocyte counts (mean = 636 cells/mm3). Twenty-one patients had at least one genotype during this period; no new mutations we found.
Conclusion: We believe that systematic errors in a commercial laboratory contributed to apparent virologic failures and blips in this small group of patients. Background: Antiretroviral drugs (ARV) are being provided by Govt. of India since 2004 under 3 by 5 initiative led by WHO-UNAIDS. Despite wide spread use of ARV, little information is available on the prevalence of transmitted resistance-associated mutations in HIV-1, particularly from north India. The present study was designed for molecular characterization of HIV-1 and identification of ARV resistance-associated mutations and naturally occurring genotypic variation in reverse transcriptase (RT) and protease region of pol gene of HIV-1.
Methods: Seventy ARV drug-naïve HIV-1 sero-reactive patients, newly registered in ART clinic of Lok Nayak Hospital, were enrolled in the study after obtaining written e248 14th International Congress on Infectious Diseases (ICID) Abstracts informed consent. Plasma HIV-1 RNA levels were estimated by Amplicor HIV-1 Monitor test V 1.5 (Roche Diagnostics). HIV-1 pol gene, enconsisting protease region (codons;1-99) and RT region (codons;1-232 to 1-239) was reverse transcribed, followed by nested PCR with self designed primers. The PCR product was sequenced with an ABI PRISM 3100 genetic analyzer system.
Results: The median HIV-1 RNA levels were log10 4.6 copies/ml (IQR; 4.2-5.3). All patients were found to be infected with HIV-1 subtype C. Only one (1.4%) study sequence harbored resistance-associated mutations in RT region, showing NRTI resistance mutation (M184I). No mutation at major resistance positions in protease region was detected. High rate of polymorphisms were observed at codons; 35, 39, 40, 48, 60, 121, 122, 123, 135, 166, 173, 174, 177, 185, 200, 204, 206, 207, 208, 211, 216, 217, 233 & 239 in RT gene and 12, 15, 18, 19, 36, 38, 41, 63, 69, 70, 89 & 93 in protease gene.
Conclusion: The overall prevalence of transmitted resistance-associated mutations was found to be 1.4%, lower than the alert cut off of 5% defined by WHO. HIV-1 subtype C exhibited enormous polymorphism in RT and protease regions of pol gene as compared to subtype B. Methods: This study was aimed to correlate clinicoradiological findings with microscopy and quantitative culture of consecutive ETA from 50 mechanically ventilated patients along with the antibiogram and risk factor assessment.
Results: The prospective observational study in MICU revealed the incidence of VAP to be 42% with a rate of 116/1000 ventilator days. 8 had early onset and 13 late onset VAP, with no age or sex significant preponderance. The attributable mortality rate was 61.9% which rose with duration of stay. The important independent risk factors were multi-organ failure, reintubation and pleural effusion. The most commonly isolated organisms were multidrug resistant Acinetobacter baumannii (76%) and Pseudomonas aeruginosa (42%). All enterobacterial isolates were ESBL producing and all S. aureus isolates were methicillin resistant. In 66%, colonization on day 1 resulted in development of VAP on day 4. Gram stain findings had a significant correlation with the quantitative culture of ETA, which by itself showed a significantly progressive increase in specificity in diagnosing VAP on day 7. The strength of association between CPIS scoring, the microbiological findings and the clinical diagnosis was found to be strong.
Conclusion: This study emphasizes that Gram stain and quantitative culture of ETA can be considered useful for the diagnosis of VAP and a combined clinical, radiological and microbiological approach can be successful in the management and further follow up of VAP. doi:10.1016/j.ijid.2010.02.2040
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Virucidal efficacy of topical antiseptics versus a novel strain of Influenza H1N1 V. Dzyakanava 1, * , K. Burningham 2 , J. Stahl 3 1 BioScience Laboratories, Bozeman, MT, USA 2 Bioscience Laboratories, Bozeman, MT, USA 3 3M Company, Saint Paul, MN, USA Background: On April 11, 2009 the WHO raised the epidemic alert to Phase 6 and declared a pandemic of novel Influenza H1N1. During the impending influenza season, the number of ''swine'' influenza cases is expected to increase, emphasizing the importance to public health of contact and respiratory hygiene. This study evaluated the susceptibility of Influenza H1N1 A/California/04/2009 strain to three topical sanitizing products, designed for application in a variety of public and healthcare settings.
Methods: ASTM E 1052-96, Standard Test Method for Efficacy of Antimicrobial Agents against Viruses in Suspension, was used to evaluate a non-medicated soap and three topical antiseptics: AvagardTM Surgical and Healthcare Personnel Hand Antiseptic (1% Chlorhexidine Gluconate, 61% Ethanol); AvagardÔ Foam Instant Hand Antiseptic (62% Ethanol); and AvagardÔ D Instant Hand Antiseptic (61% Ethanol). All products were tested at a 90% (v/v) concentration versus Influenza H1N1 A/California/04/2009 strain with exposures of 30 seconds, 1 minute, and 2 minutes. Viral titers were calculated using the Spearman-Kärber Method.
Results: All products significantly reduced infectivity of the epidemic strain of Influenza H1N1. AvagardTM (1% Chlorhexidine Gluconate, 61% Ethanol) and AvagardTM D (61% Ethanol) produced 5.25 log10 (>99.999%) reduction after 30 second exposure, as well as after 1 and 2 minute exposures. AvagardÔ Foam (62% Ethanol) reduced the viral population by 4.25 log10 (>99.99%) after 30 second, 1, and 2 minute exposures. Testing performed on non-medicated soap revealed low virucidal efficacy after short-term exposures: 2.50 log10 (99.68%) reduction after 30 second and 1 minute exposures.
Conclusion: Significant reduction (>99.99%) in the population of A/California/04/2009 strain was achieved after 30 second exposures of the virus to the hand sanitizers. In a pandemic situation, the rapid virucidal activity provides a decided advantage in reducing Influenza transmission via hand contact. doi:10.1016/j.ijid.2010.02.2041
